1-3 of 3
John F. Reilly
Close
Sort by
Journal Articles

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Clinical Trials & Observations
Guillermo Garcia-Manero, Hui Yang, Carlos Bueso-Ramos, Alessandra Ferrajoli, Jorge Cortes, William G. Wierda, Stefan Faderl, Charles Koller, Gail Morris, Gary Rosner, Andrey Loboda, Valeria R. Fantin, Sophia S. Randolph, James S. Hardwick, John F. Reilly, Cong Chen, Justin L. Ricker, J. Paul Secrist, Victoria M. Richon, Stanley R. Frankel, Hagop M. Kantarjian
Journal: Blood
Blood (2008) 111 (3): 1060–1066.
https://doi.org/10.1182/blood-2007-06-098061
Published: 2008
Includes: Supplemental data
Journal Articles

High Expression and Persistent Activation of STAT1, 3 and 5 Predicts Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Resistance in Cutaneous T-Cell Lymphoma Cells.

Valeria R. Fantin, PhD, Andrey Loboda, PhD, Jennifer A. Roth, Cloud Paweletz, PhD, Sophia Randolph, MD, PhD, Jacqueline W. Pierce, PhD, Elizabeth A. Harrington, PhD, Ronald C. Hendrickson, PhD, John F. Reilly, PhD, Christopher Ware, Marshall E. Kadin, MD, Madeleine Duvic, MD, Stanley R. Frankel, MD, Victoria M. Richon, PhD
Journal: Blood
Blood (2006) 108 (11): 4679.
https://doi.org/10.1182/blood.V108.11.4679.4679
Published: 2006
Journal Articles

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Clinical Trials & Observations
Madeleine Duvic, Rakshandra Talpur, Xiao Ni, Chunlei Zhang, Parul Hazarika, Cecilia Kelly, Judy H. Chiao, John F. Reilly, Justin L. Ricker, Victoria M. Richon, Stanley R. Frankel
Journal: Blood
Blood (2006) 109 (1): 31–39.
https://doi.org/10.1182/blood-2006-06-025999
Published: 2006